Pulmonx Corporation (NASDAQ:LUNG) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Pulmonx Corporation (NASDAQ:LUNG) has received a consensus rating of "Moderate Buy" from analysts, with four maintaining a hold rating and five issuing buy ratings. The average one-year price target is approximately $7.66.
• Insider activity includes Director Daniel P. Florin acquiring 23,321 shares at $3.06 each, indicating a 24.83% increase in his stake, while CEO Steven S. Williamson sold 9,923 shares at $3.13, representing a 2.64% decrease in his ownership.
• The company's latest quarterly earnings reported ($0.38) earnings per share, surpassing estimates by $0.02, with revenue of $23.86 million against expectations of $23.46 million.

Pulmonx Corporation (NASDAQ:LUNG - Get Free Report) has been given a consensus rating of "Moderate Buy" by the nine ratings firms that are currently covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $7.6643.

A number of equities research analysts recently commented on LUNG shares. Lake Street Capital dropped their target price on Pulmonx from $12.00 to $8.00 and set a "buy" rating on the stock in a research report on Thursday, July 31st. Wells Fargo & Company dropped their target price on Pulmonx from $6.00 to $3.00 and set an "equal weight" rating on the stock in a research report on Friday, August 1st. Canaccord Genuity Group dropped their target price on Pulmonx from $16.00 to $15.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st. Wall Street Zen lowered Pulmonx from a "hold" rating to a "sell" rating in a research report on Saturday, August 2nd. Finally, Piper Sandler lowered Pulmonx from an "overweight" rating to a "neutral" rating and dropped their target price for the company from $9.00 to $2.50 in a research report on Thursday, July 31st.

Insiders Place Their Bets

In related news, Director Daniel P. Florin acquired 23,321 shares of the stock in a transaction on Thursday, June 5th. The shares were acquired at an average price of $3.06 per share, for a total transaction of $71,362.26. Following the transaction, the director owned 117,231 shares in the company, valued at approximately $358,726.86. This trade represents a 24.83% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Steven S. Williamson sold 9,923 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $3.13, for a total value of $31,058.99. Following the completion of the sale, the chief executive officer owned 366,115 shares in the company, valued at approximately $1,145,939.95. This represents a 2.64% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 43,388 shares of company stock worth $136,044. Corporate insiders own 6.80% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in LUNG. Wells Fargo & Company MN lifted its position in shares of Pulmonx by 48.7% during the 4th quarter. Wells Fargo & Company MN now owns 18,418 shares of the company's stock valued at $125,000 after buying an additional 6,033 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Pulmonx by 38.7% during the 4th quarter. Renaissance Technologies LLC now owns 220,510 shares of the company's stock valued at $1,497,000 after buying an additional 61,500 shares in the last quarter. XTX Topco Ltd purchased a new position in shares of Pulmonx during the 4th quarter valued at approximately $146,000. Dimensional Fund Advisors LP lifted its position in shares of Pulmonx by 17.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 408,022 shares of the company's stock valued at $2,770,000 after buying an additional 60,489 shares in the last quarter. Finally, Stifel Financial Corp purchased a new position in shares of Pulmonx during the 4th quarter valued at approximately $81,000. Hedge funds and other institutional investors own 91.04% of the company's stock.

Pulmonx Price Performance

Shares of LUNG stock opened at $1.69 on Monday. Pulmonx has a fifty-two week low of $1.47 and a fifty-two week high of $9.37. The firm has a market capitalization of $68.87 million, a price-to-earnings ratio of -1.18 and a beta of 0.43. The company has a debt-to-equity ratio of 0.54, a quick ratio of 4.63 and a current ratio of 5.35. The stock's 50-day simple moving average is $2.44 and its 200-day simple moving average is $4.47.

Pulmonx (NASDAQ:LUNG - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported ($0.38) earnings per share for the quarter, topping analysts' consensus estimates of ($0.40) by $0.02. The business had revenue of $23.86 million for the quarter, compared to analyst estimates of $23.46 million. Pulmonx had a negative return on equity of 69.76% and a negative net margin of 62.88%. Pulmonx has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Pulmonx will post -1.55 earnings per share for the current fiscal year.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.